(Adnkronos) - I pazienti che soffrono di insufficienza cardiaca, patologia che colpisce il 10% della popolazione italiana over 65, possono da oggi contare su un nuovo farmaco. L’Aifa si è infatti espressa positivamente sulla rimborsabilità di vericiguat, il nuovo farmaco per il trattamento dell’insufficienza cardiaca sintomatica cronica sviluppato da Bayer. La notizia dell’ottenuta rimborsabilità è stata al centro della conferenza stampa organizzata a Milano dalla società farmaceutica, alla quale hanno partecipato Fabrizio Oliva, presidente Anmco; Pasquale Perrone Filardi, presidente Sic e Maurizio Volterrani, presidente nazionale Itahfa.
Category
🗞
NewsTranscript
00:00 [Music]
00:04 Characterized by the inability of the heart to have adequate contractility,
00:08 cardiac insufficiency is a syndrome that can arise for various reasons,
00:12 from ischemic cardiopathy, valve pathologies,
00:14 to hypertension not properly treated and heart muscle diseases.
00:19 The main symptoms are fatigue, lack of breath,
00:22 fluid retention and difficulty in performing normal daily activities.
00:26 It is a pathology that affects about 600,000 people in Italy.
00:32 The prevalence increases with age and over 65 years we are around 10% of prevalence.
00:40 The proper dosage of the four classes of drugs that represent the four pillars
00:44 of the treatment of heart failure is essential to alleviate the risk of reacutization.
00:49 However, some patients, although treated with all the drugs available,
00:54 continue to show signs of worsening and reacutization episodes.
00:58 A new therapeutic option is now available for them.
01:02 It is vericiguat, a drug with an innovative action mechanism
01:06 that has obtained the free way to reimbursement from AIFA.
01:10 We have new drugs that have changed the history of the disease in the patient.
01:19 In particular, there is a drug called vericiguat,
01:24 which has a precise indication in this type of patient.
01:30 The Victoria registrative study on the effectiveness of the new Bayer drug
01:34 has in fact highlighted a specific indication for patients with heart failure
01:39 who had been subjected to recent hospitalizations and who had suffered reacutizations,
01:44 despite the therapy already in place.
01:46 Vericiguat has proven effective in reducing the risk of hospitalization by 4.2% in absolute terms.
01:53 This is an intelligent drug that stimulates the activity of an enzyme called guanylate cyclase
01:59 and therefore gives the availability of molecules,
02:02 the GMP cycle produced by guanylate cyclase,
02:05 which have variations on various organs and devices, from blood vessels to cardiomyocytes, etc.,
02:11 so that in the end the beneficial effect is achieved both at the myocardial and vascular level.
02:16 go at it.
02:16 [BLANK_AUDIO]